II. Definitions
- Opiate
 - Opioids
- Includes Opiates (naturally occurring)
 - Semi-synthetic Opioids (structurally similar to Opiates)
- Examples: Hydrocodone, Oxycodone, Hydromorphone, Oxymorphone
 
 - Synthetic Opioids
- Examples: Methadone, Buprenorphine, Meperidine, Fentanyl, Tramadol
 
 
 
III. Adverse Effects
- See Opioid Adverse Effect
 - See Opioid Overdose
 - See Opioid Abuse
 - See Opioid Withdrawal
 
IV. Pharmacology: Metabolism of Opioids
- Common Metabolites
- Codeine: Metabolizes to Hydrocodone and Morphine
 - Heroin: Metabolizes to 6-acetylmorphine (6-MAM) and then to Morphine
 - Morphine and Hydrocodone: metabolize to Hydromorphone
 - Hydrocodone: Metabolizes to Dihydrocodeine
 - Oxycodone: Metabolizes to Oxymorphone
 
 - Renal dysfunction
 - Hepatic dysfunction
 - References
- Johnson (2007) Opioid Safety in Patients With Renal or Hepatic Dysfunction, Pain Treatment Topics
 
 
V. Pharmacology: Mechanism
- Opiate receptor Agonists in-vivo are triggered by stress and pain
- Opium derivatives (e.g. Morphine) and synthetics mimic endogenous Opioid-like agents
- CNS Opiate receptor binding results in analgesia and euphoria
 - Receptor types include mu, kappa and delta receptors
 
 - Endogenous Opioid-like agents
- Endorphins
 - Enkephalins
 - Dynorphins
 
 - Endogenous Opioids are synthesized from Protein precursors
- Pro-opiomelanocortin (POMC, also a precursor for ACTH and Melanocyte Stimulating Hormone)
 - Proenkephalin
 - Prodynorphin
 
 
 - Opium derivatives (e.g. Morphine) and synthetics mimic endogenous Opioid-like agents
 - Opiate receptors are concentrated in the periqueductal gray matter (as well as other CNS regions)
 - Opioids bind Neuron membrane receptors
 - Cells become hyperpolarized
- Charge difference increases between intracellular and extracellular fluid
 - Decreases likelihood of Neuron activation (firing) in response to a given Action Potential
 
 - Sensory Neurons decrease activity
- Results in fewer afferent, sensory signals returning to CNS
 - Pain Sensation is therefore reduced
 
 - Overall Opiate Receptor Agonist Effects
- Analgesia
 - Sedation
 - Respiratory depression
 - Gastrointestinal side effects (Nausea, Vomiting, ileus, Constipation)
 - Miosis
 - Antidiuretic Hormone release
 
 
VI. Approach: Quantity Prescribed
VII. Precautions: General
- Informed Consent for Opioid Prescription
 - Pregnancy
- Neural Tube Defects if Opioids used in early pregnancy
 - Newborn Opioid Withdrawal (neonatal abstinence syndrome) if maternal Chronic Opioid use
 - No evidence of Tramadol safety
 - Buprenorphine (without Naloxone) or Methadone may be used for pregnant women with Opioid Use Disorder
 - (2017) Presc Lett 24(11): 64
 - (2017) Obstet Gynecol 130(2):e81-e94 +PMID:28742676 [PubMed]
 - Reddy (2017) Obstet Gynecol 130(1):10-28 +PMID:28594753 [PubMed]
 
 - Respiratory Depression
- Exercise caution in comorbid COPD, Obstructive Sleep Apnea and other respiratory disorders
 - Avoid in combination with CNS Depressants (e.g. Benzodiazepines, Z-Drugs)
 
 
VIII. Precautions: Ineffective Oral Opioids (Not recommended)
- 
                          Darvocet N-100 (Acetaminophen 650, Propoxyphene 100)
- Dose: 1 PO q4-6 hours
 - Not available in U.S. as of 2007-2010
 - Not recommended due to low efficacy and toxicity risk
 
 - 
                          Tylenol #3 (Acetaminophen 300, Codeine 30)
- Dose: 1-2 PO q4-6 hours
 - Avoid due to low efficacy and increased toxicity risk
 
 
IX. Precautions: Metabolism and Drug Interactions
- Severe liver disease (Cirrhosis)
- Fentanyl is preferred (Pharmacokinetics are not significantly affected)
 - Consider oral Opioid dose reduction to 50% and increasing dosing frequency (due to decreased first pass metabolism)
 - Avoid Morphine (increased Bioavailability and decreased clearance)
 
 - Renal Failure (or Chronic Kidney Disease 4 or 5)
 - Elderly
- Increased adverse effect risk (altered Pharmacokinetics, Polypharmacy, Fall Risk)
 - Fewer Analgesic alternatives (avoid NSAIDS)
 - Avoid Tramadol
 - Start oral Opioids at 25 to 50% of normal dose
 
 - 
                          Serotonin Syndrome
                          
- Risk with serotonergic Opioids (e.g. Tramadol, Fentanyl, Meperidine, Methadone)
 - Avoid combining with other serotonergic agents (e.g. SSRIs)
 
 - Variable metabolism of oral Opioids
- Most oral Opioids are metabolized to active form (e.g. Morphine) by Cytochrome P450 2D6 (CYP2D6)
 - Ultrarapid CYP2D6 Metabolizers
- Accounts for 10% of caucasians (may be as high as 30% in some races)
 - Risk of a rapid conversion to toxic levels of active Opioid (e.g., Morphine)
 
 - Slow CYP2D6 Metabolizers
- Accounts for 10% of caucasians (or 3% of other races)
 - Renders the oral Opioids less effective in slow metabolizing patients
 
 - CYP3A4 Inhibitors (e.g. Itraconazole, Ritonavir)
- May increase levels of Hydrocodone, Oxycodone, Fentanyl
 
 
 - References
- (2024) Presc Lett 31(6): 35
 - (2012) Presc Lett 19(6): 33
 - Crews (2012) Clin Pharmacol Ther 91:321-6 [PubMed]
 
 
X. Precautions: Iatrogenic Opioid Overdose prevention
- Avoid repeat intramuscular Opioid injection
- Risk of dose stacking and secondary CNS/Respiratory depression (esp. Dilaudid)
 
 - Titrate dosing to pain while exercising caution in the elderly and Opioid naive
- See Dilaudid below for specific precautions
 - Decrease dose to 50% in the elderly, hepatic insufficiency, Renal Insufficiency
 
 - Opioid tolerant patients may still experience respiratory depression on typical Opioid doses
 - Exercise caution when combining CNS Depressants (e.g. Opioids and Benzodiazepines)
 - Long-acting Opioids for non-cancer Chronic Pain are associated with significantly increased mortality
 - References
 
XI. Medications: Acute pain IV Opioids (equivalent to Demerol 50 mg IV)
- 
                          Fentanyl 50 mcg IV (25 mcg IV in elderly)
- Preferred agent in Renal Insufficiency
 - Onset <1 minute
 - Peaks 2 to 5 minutes
 - Duration 30 to 60 minutes
 
 - 
                          Morphine 4 mg IV (2 mg IV in elderly)
- Onset 1 to 2 minutes
 - Peaks 3 to 5 minutes
 - Duration 1 to 2 hours
 
 - 
                          Hydromorphone (Dilaudid)
- Onset 5 to 15 minutes
 - Peaks 10 to 20 minutes
 - Duration 2 to 4 hours
 - Moderate pain: 0.5 mg IV
- Start with 0.2 to 0.3 mg IV in the elderly or Opioid naive
 - May repeat every 15 to 30 minutes up to 3 doses in the emergency department
- Spread interval to every 2-3 hours on the hospital ward
 
 
 - Opioid tolerant or severe pain: Start with 1 mg IV
 - Dilaudid triggers greater euphoria than Fentanyl or Morphine (higher risk of drug seeking and abuse)
 - Dilaudid is a high potency Opioid (1 mg is equivalent to up to 10 mg Morphine)
- Most iatrogenic Opioid Overdoses have occurred with Hydromorphone (Dilaudid)
 
 
 
XII. Medications: Oral Opioids by strength
- Weak Opioids (WHO Step 2)
- Vicodin (Hydrocodone 5, Acetaminophen 500)
- Dose: 1-2 PO q4-6 hours
 - Hydrocodone 10 mg equivalent to Codeine 60-80 mg
 
 - Vicoprofen (Hydrocodone 7.5, Ibuprofen 200)
- Dose: 1-2 PO q4-6 hours
 
 - Tramadol (Ultram)
 
 - Vicodin (Hydrocodone 5, Acetaminophen 500)
 - Strong Opioids (WHO Step 3)
- Oxycodone
- Adults (and over age 12 years) 5-10 mg every 4-6 hours as needed
 - Child: 0.05 to 0.3 mg/kg/dose (up to 10 mg) every 4-6 hours as needed
 
 - Percocet (Acetaminophen 325, Oxycodone 5)
- Dose: 1 PO q6 hours (adults)
 
 - Hydromorphone (Dilaudid)
- Dose: 2 mg orally every 4-6 hours
 
 - Morphine Sulfate (MSIR, MS Contin)
- Fast Release: 15 to 30 mg orally every 4 hours
 - Sustained Release (MS Contin): 30 mg orally every 8-12 hours
 
 - Fentanyl Lollipop (100 ug, 200 ug, 300 ug, 400 ug)
- Dose: 5 to 15 ug/kg (maximum 400 ug)
 
 - Methadone (Dolophine)
- Dose: 15 to 60 mg orally every 6 to 8 hours
 
 
 - Oxycodone
 
XIII. Medications: Oral Opioids by duration
- Short acting Opioids
- Codeine (not recommended)
- Onset 30 to 60 minutes
 - Duration 4 to 6 hours
 
 - Tramadol (not recommended)
- Onset 1 hour
 - Duration 4 to 6 hours
 
 - Hydrocodone (e.g. Vicodin orally every 6 hours)
- Onset 30 to 60 minutes
 - Duration 4 to 6 hours
 
 - Oxycodone IR (e.g. Percocet orally every 6 hours)
- Onset 10 to 15 minutes
 - Duration 3 to 6 hours
 
 - Morphine Sulfate IR (e.g. MSIR 10 mg orally every 4 hours)
- Onset 30 minutes
 - Peaks 1 hour
 - Duration 3 to 5 hours
 
 - Hydromorphone (e.g. 4 mg orally every 4 hours)
- Onset 15 to 30 minutes
 - Peaks 30 to 60 minutes
 - Duration 3 to 4 hours
 
 
 - Codeine (not recommended)
 - Long acting Opioids
 
XIV. Medications: MME - Morphine Equivalent Opioid Doses
XV. Medications: Transdermal Opioid
XVI. Medications: Transmucosal Opioid
XVII. Medications: Rectal Opioids
XVIII. Medications: By origin (natural Opiates, semi-sythetic and synthetic Opioids)
- Naturally occurring Opiates (opium poppy derivatives, subset of Opioids)
 - Semi-synthetic Opioids (structurally similar to Opiates)
- Hydrocodone
 - Oxycodone
 - Hydromorphone
 - Oxymorphone
 
 - Synthetic Opioids
 
XIX. Medications: Opioid Abuse deterrents (e.g. Tamper resistant)
- Precautions
- Abuse deterrents are inconsistent among products
- Long-acting Hydrocodone (Zohydro) is not tamper resistant
 
 - Abuse deterrents are not shown to reduce abuse
- abuse deterrent may simply offset abuse to other substances (e.g. Heroin)
 
 - Abuse deterrents increase Opioid costs up to four fold
 
 - Abuse deterrents are inconsistent among products
 - Agents with abuse deterrents
- Opioids with abuse Antagonists
- Buprenorphine with Naloxone (Suboxone, Zubsolv)
 
 - Opioids with tamper resistance (e.g. break into clumps when crushed or thick gel when wet)
- Long-Acting Oxycodone (Oxycontin)
 - Extended Release Hydromorphone (Exalgo)
 
 - Implantable Opioids
- Buprenorphine implant (Probiphine)
 
 
 - Opioids with abuse Antagonists
 - References
- (2014) Presc Lett 21(5): 28
 
 
XX. Medications: Adjunctive
- Alternative non-Opioids
 - Stool Softeners or Laxatives
 
XXI. References
- Dachs (2003) AAFP Board Review, Seattle
 - Hipskind and Kamboj (2016) Crit Dec Emerg Med 30(10): 15-23
 - Velasco and Kiel (2023) Crit Dec Emerg Med 37(1): 4-9
 - (2000) Tarascon Pocket Pharmacopoeia
 - (2000) Med Lett Drugs Ther 42(1085):73-8 [PubMed]